View in EDS HTML Full Text PDF Full Text

Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine.

Saved in:
Bibliographic Details
Title: Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Authors: Robblee, Jennifer, Devick, Katrina L., Mendez, Natasha, Potter, Jamie, Slonaker, Jennifer, Starling, Amaal J.
Source: Headache: The Journal of Head & Face Pain. Oct2020, Vol. 60 Issue 9, p2014-2025. 12p.
Subjects: Migraine prevention, Injections, Migraine, Monoclonal antibodies, Scientific observation, Patient satisfaction, Preventive health services, Research, Treatment effectiveness, Retrospective studies, Patients' attitudes, Descriptive statistics, Tertiary care
Abstract: Background: Erenumab, a calcitonin gene‐related peptide (CGRP) receptor monoclonal antibody, has been well tolerated with good efficacy for the preventive treatment of episodic and chronic migraine in phase 2 and phase 3 clinical trials. Limited post‐market observations are available to validate these findings in a real‐world tertiary headache clinic population with complex comorbidities and refractory migraine. Objective: The goal of this study is to demonstrate the real‐world performance of erenumab among patients in a tertiary care headache clinic by describing patient selection, experience, and clinical characteristics after 6 months of erenumab therapy. Methods: A retrospective, exploratory, observational study was conducted on patients receiving at least 1 erenumab injection (70 or 140 mg). Baseline data obtained by chart review and telephone calls were compared to 6‐month follow‐up telephone calls. The primary outcome was the reduction in self‐reported headache days per month at baseline compared to 6 months for those with complete 6‐month data. The significance level was set at P <.05. Secondary analyses explored the distribution of headache severity, responder rates, Migraine Disability Assessment scores, adverse effects, ineffective preventives, comorbidities, wearing‐off, and discontinuation. Results: Of the 101 patients who consented to participate, 89.1% (90/101) were women, and the mean age of all patients was 49 years (range, 19‐80 years). At baseline, 94.1% (95/101) of patients had chronic migraine, 5.0% (5/101) had episodic migraine, and 18.8% (19/101) had medication overuse headache. The mean (SD) number of baseline headache and migraine days per month for the entire cohort were 24.3 (8.2) and 18.2 (9.3) days, respectively. Participants had numerous comorbidities and had tried a mean of 11.2 unique oral medications and 4.8 unique medication categories before receiving erenumab, including 83.2% (84/101) who had also received onabotulinumtoxinA. Six‐month post‐erenumab follow‐up data were available for 42.6% (43/101) of participants. For these 43 participants, the number of headache days per month decreased significantly by 6.5 days from a baseline mean (SD) of 24.8 (6.47) days to 18.3 (12) days at 6‐month follow‐up (P <.001); similarly, the monthly migraine days decreased significantly by 8.4 days from a baseline mean of 19.1 (9.3) days to 10.7 days at 6‐month follow‐up (P <.001). The 50% responder rate was 34.9% (15/43) for monthly headache days and 54.8% (23/43) for monthly migraine days. Of all 101 participants, 28 (27.7%) discontinued erenumab, primarily because it was ineffective (39.3%, 11/28) or because of adverse effects (42.9%, 12/28). Conclusion: This post‐market observational study of patient experience describes response to erenumab in a real‐world tertiary headache clinic with a complex patient population. Overall, these complex patients had a significant positive clinical response to erenumab, but with high rates of discontinuation. This study also noted a 1‐week wearing‐off response and high rates of constipation. Further post‐market studies are needed to better characterize patient selection and real‐world response to erenumab. [ABSTRACT FROM AUTHOR]
Copyright of Headache: The Journal of Head & Face Pain is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 146138619
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Robblee%2C+Jennifer%22&quot;&gt;Robblee, Jennifer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Devick%2C+Katrina+L%2E%22&quot;&gt;Devick, Katrina L.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mendez%2C+Natasha%22&quot;&gt;Mendez, Natasha&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Potter%2C+Jamie%22&quot;&gt;Potter, Jamie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Slonaker%2C+Jennifer%22&quot;&gt;Slonaker, Jennifer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Starling%2C+Amaal+J%2E%22&quot;&gt;Starling, Amaal J.&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Headache%3A+The+Journal+of+Head+%26+Face+Pain%22&quot;&gt;Headache: The Journal of Head &amp; Face Pain&lt;/searchLink&gt;. Oct2020, Vol. 60 Issue 9, p2014-2025. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Migraine+prevention%22&quot;&gt;Migraine prevention&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Injections%22&quot;&gt;Injections&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Migraine%22&quot;&gt;Migraine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Monoclonal+antibodies%22&quot;&gt;Monoclonal antibodies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Scientific+observation%22&quot;&gt;Scientific observation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Patient+satisfaction%22&quot;&gt;Patient satisfaction&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Preventive+health+services%22&quot;&gt;Preventive health services&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research%22&quot;&gt;Research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Treatment+effectiveness%22&quot;&gt;Treatment effectiveness&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Retrospective+studies%22&quot;&gt;Retrospective studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Patients&#39;+attitudes%22&quot;&gt;Patients&#39; attitudes&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Descriptive+statistics%22&quot;&gt;Descriptive statistics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Tertiary+care%22&quot;&gt;Tertiary care&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Erenumab, a calcitonin gene‐related peptide (CGRP) receptor monoclonal antibody, has been well tolerated with good efficacy for the preventive treatment of episodic and chronic migraine in phase 2 and phase 3 clinical trials. Limited post‐market observations are available to validate these findings in a real‐world tertiary headache clinic population with complex comorbidities and refractory migraine. Objective: The goal of this study is to demonstrate the real‐world performance of erenumab among patients in a tertiary care headache clinic by describing patient selection, experience, and clinical characteristics after 6 months of erenumab therapy. Methods: A retrospective, exploratory, observational study was conducted on patients receiving at least 1 erenumab injection (70 or 140 mg). Baseline data obtained by chart review and telephone calls were compared to 6‐month follow‐up telephone calls. The primary outcome was the reduction in self‐reported headache days per month at baseline compared to 6 months for those with complete 6‐month data. The significance level was set at P &lt;.05. Secondary analyses explored the distribution of headache severity, responder rates, Migraine Disability Assessment scores, adverse effects, ineffective preventives, comorbidities, wearing‐off, and discontinuation. Results: Of the 101 patients who consented to participate, 89.1% (90/101) were women, and the mean age of all patients was 49 years (range, 19‐80 years). At baseline, 94.1% (95/101) of patients had chronic migraine, 5.0% (5/101) had episodic migraine, and 18.8% (19/101) had medication overuse headache. The mean (SD) number of baseline headache and migraine days per month for the entire cohort were 24.3 (8.2) and 18.2 (9.3) days, respectively. Participants had numerous comorbidities and had tried a mean of 11.2 unique oral medications and 4.8 unique medication categories before receiving erenumab, including 83.2% (84/101) who had also received onabotulinumtoxinA. Six‐month post‐erenumab follow‐up data were available for 42.6% (43/101) of participants. For these 43 participants, the number of headache days per month decreased significantly by 6.5 days from a baseline mean (SD) of 24.8 (6.47) days to 18.3 (12) days at 6‐month follow‐up (P &lt;.001); similarly, the monthly migraine days decreased significantly by 8.4 days from a baseline mean of 19.1 (9.3) days to 10.7 days at 6‐month follow‐up (P &lt;.001). The 50% responder rate was 34.9% (15/43) for monthly headache days and 54.8% (23/43) for monthly migraine days. Of all 101 participants, 28 (27.7%) discontinued erenumab, primarily because it was ineffective (39.3%, 11/28) or because of adverse effects (42.9%, 12/28). Conclusion: This post‐market observational study of patient experience describes response to erenumab in a real‐world tertiary headache clinic with a complex patient population. Overall, these complex patients had a significant positive clinical response to erenumab, but with high rates of discontinuation. This study also noted a 1‐week wearing‐off response and high rates of constipation. Further post‐market studies are needed to better characterize patient selection and real‐world response to erenumab. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Headache: The Journal of Head &amp; Face Pain is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=146138619
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/head.13951
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 2014
    Subjects:
      – SubjectFull: Migraine prevention
        Type: general
      – SubjectFull: Injections
        Type: general
      – SubjectFull: Migraine
        Type: general
      – SubjectFull: Monoclonal antibodies
        Type: general
      – SubjectFull: Scientific observation
        Type: general
      – SubjectFull: Patient satisfaction
        Type: general
      – SubjectFull: Preventive health services
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Retrospective studies
        Type: general
      – SubjectFull: Patients' attitudes
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Tertiary care
        Type: general
    Titles:
      – TitleFull: Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Robblee, Jennifer
      – PersonEntity:
          Name:
            NameFull: Devick, Katrina L.
      – PersonEntity:
          Name:
            NameFull: Mendez, Natasha
      – PersonEntity:
          Name:
            NameFull: Potter, Jamie
      – PersonEntity:
          Name:
            NameFull: Slonaker, Jennifer
      – PersonEntity:
          Name:
            NameFull: Starling, Amaal J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 00178748
          Numbering:
            – Type: volume
              Value: 60
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Headache: The Journal of Head & Face Pain
              Type: main
ResultId 1